Indications and administration practices amongst medical cannabis healthcare providers: a cross-sectional survey.

A study published in BMC Family Practice sought to characterize the clinical practice characteristics of medical professionals who recommend cannabis.

Labeling of Cannabidiol Products: A Public Health Perspective

Authors: Jamie Corroon, Douglas MacKay, William Dolphin
Cannabis and Cannabinoid Research, 6 March 2020

Introduction: Interest in the therapeutic use of cannabidiol (CBD) has reached a fever-pitch in recent months, as CBD-containing products appear everywhere from online retailers to grocery stores and gas stations. The widespread availability of hemp-derived CBD products is con…

Cannabis education needs assessment among Canadian physicians-in-training.

Canadian researchers found that the average training from physicians in training was 25% less than what they desired and that further training was paramount for them to engage in cannabis for therapeutic purposes (2020).

Medical students are unprepared to counsel patients about medical cannabis and want to learn more.

Authors: Abraham Benavides, Nicholas Gregorio, Puneet Gupta, Mikhail Kogan
Complementary Therapies in Medicine, January 2020

Introduction: Over-the-counter and prescribed medical cannabis products are used by patients for various conditions including psychiatric disorders, pain management, and other neurodegenerative conditions.1 Despite this growing public interest and increasing legal availability…

A National Needs Assessment of Canadian Nurse Practitioners Regarding Cannabis for Therapeutic Purposes.

Authors: Lynda G. Balneaves, Abeer Alraja, Daniel Ziemianski, Fairleth McCuaig, Mark Ware
Cannabis and Cannabinoid Research, March 2018

Introduction: In Canada, the Access to Cannabis for Medical Purposes Regulations (ACMPR) has given nurse practitioners (NPs) the power to authorize cannabis for therapeutic purposes (CTP) to eligible patients. This expansion in NPs’ scope of practice underscores the importance…

A history of the Society of Cannabis Clinicians and its contributions and impact on the US medical cannabis movement

Dr. Kevin M.Takakuwa details the history of the SCC, which is the first and oldest U.S. medical organization promoting the use of medical cannabis.

Serious adverse effects of cannabidiol (CBD): a review of randomized controlled trials.

Authors: Rafael G. dos Santos, Francisco S. Guimarães, José Alexandre S. Crippa, et al
Expert Opinion on Drug Metabolism & Toxicology, 9 April 2020

Introduction: Recent trials using cannabidiol (CBD) have shown that most acute and prolonged adverse effects of CBD are mild to moderate, with rare serious adverse effects (SAEs). This review focused on analyzing SAEs of CBD and their possible relation to drug-drug interaction…

Current Status and Future of Cannabis Research

Authors: Ethan B. Russo, Alice P. Mead, Dustin Sulak
Clinical Researcher, April 2015

Although cannabis is primarily viewed by the public as a recreational drug or agent of abuse, its medical application spans recorded history.1,2 Evolution has yielded a cannabis plant that produces a family of some 100 chemicals called phytocannabinoids (“plant cannabinoids”)…

Adverse effects of cannabidiol: a systematic review and meta-analysis of randomized clinical trials.

Authors: Edward Chesney, Dominic Oliver, Alastair Green, Simina Sovi, Jack Wilson, Amir Englund, et al
Neuropsychopharmacology, 8 April 2020

Cannabidiol (CBD) is being investigated as a treatment for several medical disorders but there is uncertainty about its safety. We conducted the first systematic review and meta-analysis of the adverse effects of CBD across all medical indications. Double-blind randomized plac…

Medical marijuana laws and adolescent marijuana use in the USA from 1991 to 2014: results from annual, repeated cross-sectional surveys.

Authors: Deborah S. Hasin, Melanie Wall, Katherine M. Keyes, Magdalena Cerdá, John Schulenberg, et al
The Lancet Psychiatry, July 2015

BACKGROUND: Adolescent use of marijuana is associated with adverse later effects, so the identification of factors underlying adolescent use is of substantial public health importance. The relationship between US state laws that permit marijuana for medical purposes and adoles…

Medical Marijuana: Is the Cart Before the Horse?

Authors: Deepak Cyril D’Souza, Mohini Ranganathan
JAMA, 23 June 2015

There is a pressing need to develop new medications for many debilitating conditions. Novel approaches based on marijuana or its constituent cannabinoids, if proven, could be added to the armamentarium of available treatments. In this issue of JAMA, reviews by Whiting et al1 a…

Cannabinoid Dose and Label Accuracy in Edible Medical Cannabis Products.

Authors: Ryan Vandrey, Jeffrey C. Raber, Mark E. Raber, Brad Douglass, Cameron Miller, Marcel O. Bonn-Miller
JAMA, 23 June 2015

As the use of cannabis (marijuana) for medical purposes has expanded, a variety of edible products for oral consumption has been developed. An estimated 16% to 26% of patients using medical cannabis consume edible products.1,2 Even though oral consumption lacks the harmful by-…